Amy Barton Pai, Pharm.D., BCPS, FASN, FCCP

Bio: 

Education

Nephrology Fellowship, University of Illinois at Chicago 
Pharmacy Practice Residency, St. Peter’s Hospital
NIH-General Clinical Research Center Scholar’s Program, University of New Mexico
Pharm.D., Albany College of Pharmacy and Health Sciences 
B.S. Pharm, Albany College of Pharmacy and Health Sciences

Other Academic Appointments

Adjunct Associate Professor of Medicine, Albany Medical College, Albany, NY 
Associate Professor, University of New Mexico College of Pharmacy and School of Medicine (2001-2008)

Teaching Experience

Pharmacotherapy - Acute Kidney Injury, Clinical Pharmacokinetics
Integrated Problem Solving-Coordinator
Advanced Pharmacy Practice Experience

Research Interests

Dr. Barton Pai’s clinical and translational research program focuses on oxidative stress and inflammation in chronic kidney disease (CKD) patients. Her laboratory conducts in vivo and in vitro investigations of the effects intravenous iron compounds, vitamin D and other pharmaceuticals on cytokine activation, reactive oxygen species formation and lipid peroxidation to better understand the potential effects of the agents on cardiovascular disease in patients with kidney disease. Other research interests include pharmacokinetics and drug metabolism in CKD, effects of iron on gram-positive organism growth and infection and outcomes related to clinical pharmacy interventions in CKD patients. 

Dr. Barton Pai is also dedicated to training programs for aspiring clinical pharmacy scientists.

Honors and Achievements

Fellow, American Society of Nephrology
Fellow, American College of Clinical Pharmacy

Selected Publications

Pai AB, McQuade C, Olp J. Hicks P, Conner T.  Non-transferrin Bound Iron (NTBI), Cytokine Activation and Intracellular Reactive Oxygen Species Generation in hemodialysis (HD) Patients Receiving Iron Dextran (ID) or Iron Sucrose (IS). Biometals 2011; Jan 13 

Gupta A, Zhuo J, Zha J, Reddy S, Olp J, Pai AB. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrology 2010:11;16 

Pai AB, Nielson JC, Kausz A, Miller P, Owen J. Plasma Pharmacokinetics of two consecutive doses of ferumoxytol in Healthy Subjects. Clin Pharmacol Ther 2010;June 30:1-5 

Pai AB, Depczynski JC, Martinez I, Boyd A, Khan N, Manley HJ. Reduced Drug Use Hospitalization Rates in Patients Undergoing Hemodialysis Who Received Pharmaceutical Care-a 2 year randomized, controlled study.  Pharmacotherapy. 2009;29(12):1433-1440 

Demirovic J, Pai AB, Pai MP. Creatinine Clearance Estimation in Morbidly Obese Patients. Am J Health Syst Pharm 2009;66(7)642-648 

Boyd A, McQuade CR, Cooner TA, Manley HJ, Pai AB. Correlation between the Renal Quality of Life Profile (RQLP) and Short Form−36 (SF−36) in a United States (US) Hemodialysis (HD) Population. Letter. Hemodial Int 2009;89-90 

Pai AB, Boyd A, Chavez A, Manley HJ. Health-related Quality of Life is Maintained in Hemodialysis Patients Receiving Pharmaceutical Care-A 2-Year Randomized, Controlled Study.  Hemodial Int; 2009;13:72-79 

Pai AB, Norenberg JP, Boyd A, Raj DSC, Chan L. Intravenous Iron is Associated with Increased Cytochrome P-450 3A4 (CYP3A4) Activity in Hemodialysis (HD) Patients. Clin Ther  2007;29:2699-2705 

Pai AB, Harford A, Boyd AV, McQuade C, Norenberg JP,  Zager P. Comparison of oxidative stress markers in hemodialysis patients following administration of iron dextran, sodium ferric gluconate and iron sucrose. Pharmacotherapy 2007;27:343-350. 

Boyd AV, Townsend K, Dunne A, Spalding CT Pai AB. Optimal sampling for international normalized ratios in hemodialysis patients with central venous catheters. Nephrol Nurs J 2006;33:408 

Pai AB, Depczynski J, Pai MP, McQuade C, Mercier RC. Non‑transferrin bound iron is associated with enhanced staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. Am J Nephrol 2006;26:304‑309

Associate Professor
Department of Pharmacy Practice